



**You could prevent
blindness caused
by AMD.**

AdaptDx
can help.

Functional Testing for AMD

Diagnosing age-related macular degeneration (AMD) at its earliest stages allows you to proactively slow progression of this disease — and preserve vision.

According to a 2017 study published in *JAMA Ophthalmology*,

25%

of age-related macular degeneration cases go undetected even with regular examinations using current imaging tools.¹

Additional studies show that

78%

of AMD patients do not seek first treatment until their visual acuity is irreversibly damaged. Sadly, nearly half of those patients are legally blind in one eye by the time they seek medical care.²

AdaptDx[®]

Start by testing dark adaptation function

Impaired dark adaptation is the earliest biomarker of AMD. Often manifested as night vision problems, such as difficulty seeing at night or in dim light, it becomes apparent years before drusen are visible. Therefore, assessing how well patients' eyes can adapt from bright light to darkness can be useful in diagnosing AMD at a subclinical stage.³

AdaptDx[®] is the only test for dark adaptation that can be used in a clinical setting quickly and effectively, using an objective functional measurement called the Rod Intercept[™] (RI[™]). Unlike traditional dark adaptation testing, the AdaptDx Rapid Test takes less than 6.5 minutes.

The AdaptDx dark adaptometer is:

- ✓ **Highly accurate** – correctly measures the speed of dark adaptation, which can be used to identify AMD with 90% sensitivity⁴
- 💡 **Easy to interpret** – automated, objective, functional measurement
- 💰 **Reimbursable** – using CPT code 92284 supported by more than a dozen ICD-10 codes, such as H53.62 for acquired night blindness

The AdaptDx delivers a simple, objective report

Early detection is key for optimal patient outcomes. A single number, the RI, can be useful in diagnosing AMD at the subclinical stage with the hope of preventing unnecessary vision loss.

“***I think it's excellent that my doctor has AdaptDx because it can be useful in diagnosing AMD at a very early stage. There's a history of AMD in my family so I was very motivated to take the test.***”

ALICE F, Patient

“***I have AMD, and I'm glad we caught it early, because now we can do something about it.***”

LINDA G, Patient

AdaptDx is good for your patients and your practice

Not only can AdaptDx enhance your diagnostic ability, it can dramatically increase practice revenue.

- ✓ CPT Code **92284** for dark adaptation
- ✓ \$60.63 average national reimbursement
- ✓ Monocular testing qualifies for full reimbursement
- ✓ Co-billable with OCT, imaging and/or visual field
- ✓ Multiple ICD-10 codes for initial testing and monitoring progression
- ✓ Drives revenue from auxiliary testing, plus nutraceutical and optical sales

“*I see the AdaptDx as the essential tool in AMD management. By finding the disease early and intervening appropriately, we have the best chance of altering the course.*”

THOMAS HENDERSON, MD
Eye Clinic of Austin

Applicable ICD-10 codes

Code	Description
E50.5	Vitamin A deficiency with night blindness
H35.30	Unspecified macular degeneration
H35.31XX	Non-exudative age-related macular degeneration
H35.32XX	Exudative age-related macular degeneration
H35.36X	Drusen (degenerative) of macula
H35.50	Unspecified hereditary retinal dystrophy
H35.52	Pigmentary retinal dystrophy
H35.53	Other dystrophies primarily involving the sensory retina
H35.54	Dystrophies primarily involving the RPE
H53.60	Unspecified night blindness
H53.61	Abnormal dark adaptation curve
H53.62	Acquired night blindness
H53.63	Congenital night blindness
H53.69	Other night blindness

“*AdaptDx has helped me find macular degeneration a lot earlier and proactively treat my patients. I strongly believe that if we can catch AMD at a very early stage and begin treatment, we can stop or slow this down and maintain their vision the rest of their life.*”

Laurie Sorrenson, OD, FFAO
Lakeline Vision Source

First Coast LCD L33925 deemed the following codes medically necessary for reimbursement of CPT 92284 in Florida, Puerto Rico and the Virgin Islands: E50.5, H35.50, H35.52, H35.53, H35.54, H53.60, H53.61, H53.63 and H53.69.


The diagnosis codes listed here are applicable to dark adaptation testing. The list is not intended to be exhaustive. Conversely, all Medicare, Medicaid, and private insurers may not cover all of the conditions listed. Providers should check with specific insurers to determine if there are any limitations or special instructions for claim submission.

We're here for you

Each AdaptDx purchase is supported by our **AMD Excellence Program**. We have an experienced Customer Success team who will partner with you each step of the way.

- **AdaptDx Installation** – Our Customer Success team makes it easy for you to get started by going over the details and scheduling delivery. They will collaborate with your IT staff to integrate the AdaptDx into your office network and electronic health record (EHR) system.
- **Orientation** – Your MacuLogix Practice Management Consultant (PMC) will tailor the training and integration phases of the program to maximize the value to your practice.
- **Training** – Each member of your team – doctors, technicians, front desk and billing personnel – receives in-person training.
- **Integration** – Adding dark adaptation testing to your patient evaluations can be done seamlessly. Assessing your clinical workflow, our Practice Management Consultant can incorporate dark adaptation testing into your practice protocol.
- **Optimization** – We support you through the entire process. Maintaining regular contact, we help you identify opportunities to maximize the clinical and financial benefits of the AdaptDx in your practice.

The AMD Excellence Program™



* dependent on interface with office's electronic health record provider

References

- ¹ Neely D, Bray K, Huisingh C, Clark M, et al. Prevalence of undiagnosed age-related macular degeneration in primary eye care. *JAMA Ophthalmol*. 2017;135(6):570-5.
- ² Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer, ER. Fluorescein angiographic lesion type frequency in neovascular Age-Related macular degeneration. *Ophthalmology*. 2004; 111(2), 250–255. doi.org/10.1016/j.ophtha.2003.05.030. Accessed May 23, 2018.
- ³ Owsley C, McGwin G, Clark ME, Jackson GR, et al. Delayed Rod-Mediated Dark Adaptation Is a Functional Biomarker for Incident Early Age-Related Macular Degeneration. *Ophthalmology*. October 30, 2015. doi:10.1016/j.ophtha.2015.09.041. Accessed February 6, 2018.
- ⁴ Jackson GR, Scott IU, et al. Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration. *Invest Ophthalmologist Vis Sci*. 2014;55:3:1427-31.

maculogix.com | +1 717.914.4067

©2020 MacuLogix Inc. All rights reserved. MacuLogix, the MacuLogix logo and AdaptDx are registered trademarks of MacuLogix. AMD Excellence Program is service marked by MacuLogix. MM-011 Rev 4

AdaptDx®